Summary:
Click image to enlargeSTS101 is an experimental drug/device combination product of a dihydroergotamine (DHE) dry powder formulation prefilled in a single-use delivery device for nasal administration that is being developed for the acute treatment of migraine headaches with or without aura. An experimental drug/device is not approved by the US Food and Drug Administration (FDA).
Qualified Participants Must:
• Age: 18-65
• Diagnosis of Migraines of over a year
• No more than two preventive medications
• On birth control
• No more than 15 headaches per month
• At least two migraines per month
• Migraine episodes from 4-72 hours
Qualified Participants May Receive:
compensation for time and travel